Last reviewed · How we verify
NCT04192669
Heart Rate Variability as a Clinical Marker in a Population of Anxio-depressive Patients
trial testing Heart rate monitoring in Anxio Depressive Disorder in 44 participants. Completed in 13 July 2021.
13 July 2021
Quick facts
| Lead sponsor | Tatiana Besse-Hammer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 44 |
| Start date | 11 November 2019 |
| Primary completion | 13 July 2021 |
| Estimated completion | 13 July 2021 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Heart rate monitoring
Conditions studied
- Anxio Depressive Disorder — all drugs for Anxio Depressive Disorder →
Sponsor
Tatiana Besse-Hammer
Who can join
18 and older, any sex, with Anxio Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The heart rate (HR) is regulated by the autonomic nervous system (ANS) and results from a balance between the sympathetic nervous system (SNS) that accelerates the heart rate and the parasympathetic nervous system that slows the HR via the vagus nerve. Low HRV is linked to poor emotional and cognitive regulation. Values for HRV are generally lower in depressed patients. The aim of this study is to determine how HRV could be a clinical marker that can be used in routine psychiatry practice in patients with anxio-depressive disorders, to determine the severity of symptoms and the degree of response to treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04192669
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Heart rate monitoring
Trials testing the same drug.
- NCT05887193 — Effects of Contemporary Cycling Saddle Designs on Penile Transcutaneus Oxygen and Carbon Dioxide Levels in Elite Road Cy · NA · completed
- NCT03754231 — Validation Study on RENEW's Aingeal at KK Women's and Children's Hospital · NA · completed
- NCT03134963 — Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study · completed
Other Tatiana Besse-Hammer trials
Trials by the same sponsor.
- NCT07255014 — Impact of Epidural on Trauma of the Genital Tract During Peripartum · completed
- NCT06816654 — Retrospective Evaluation of the Impact of Epidural on the Risk of Postpartum Hemorrhage · completed
- NCT04521855 — The Caregiver's Burden in Cerebral Palsy · completed
- NCT04189354 — Study of the Synergistic Effects of Biofeedback and Transcranial Electrical Stimulation in Anxio-depressive Disorders · NA · completed
- NCT03400007 — Clinical and Dynamic Floor MRI Evaluation Before and After Prolapse Surgery · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04192669 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tatiana Besse-Hammer
- Last refreshed: 19 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04192669.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing